2-O-Methyl-D-mannopyranosa

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: 2-O-Methyl-D-mannopyranosa
• 英文别名: 3,4,5,6-tetrahydroxy-2-methoxyhexanal
• 化学式: C₇H₁₄O₆
• 分子量: 194.18
• InChiKey: QRAXLHLYZJCAKB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -2.9
• 重原子数：
  13
• 可旋转键数：
  6
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.86
• 拓扑面积：
  107
• 氢给体数：
  4
• 氢受体数：
  6

文献信息

• Stabilization of deferoxamine to chelate free ions in physiological fluid
  申请人：BIOMEDICAL FRONTIERS, INC.

  公开号：EP0304183A1

  公开（公告）日：1989-02-22

  A method for scavenging free iron or aluminum in fluids such as physiological fluids involves a provision in such fluids of a soluble polymer substrate having chelator immobilized thereon. According to the invention preferred such compounds comprise polysaccarides or proteins having a deferoxamine moiety thereon. Such a compound can be used for the treatment of iron overload, as well as to inhibit cell damage from oxidation/reduction reactions. In one embodiment, cell damage during reperfusion is inhibited, through provision of the chelating moiety at the site of reperfusion.

  清除体液（如生理液）中游离铁或铝的方法是在体液中加入固定有螯合剂的可溶性聚合物基质。根据本发明，优选的此类化合物包括聚羧酸盐或蛋白质，其上有脱氧胺分子。这种化合物可用于治疗铁超载，也可用于抑制氧化/还原反应对细胞造成的损伤。在一个实施方案中，通过在再灌注部位提供螯合分子，可抑制再灌注过程中的细胞损伤。
• PHARMACEUTICAL COMPOSITION FOR CONFORMATIONAL DISEASE
  申请人：Itoham Foods Inc.

  公开号：EP2017289A1

  公开（公告）日：2009-01-21

  A pharmaceutical composition is provided which is prophylactically and/or therapeutically effective for a conformational disease typified by Alzheimer's disease, prion disease, and amyloidosis. The pharmaceutical composition of the present invention includes as an active ingredient one or more cellulose ethers selected from a cellulose ether having a structural unit represented by the general formula (1): in which at least one R is selected from CH3, C2H5, CH2CH2OH, CH2CH(OH)CH3, and CH2COOM; while other R is H; and M is selected from H, Na, K and Ca, an alkali metal salt of the cellulose ether, an aliphatic acid ester of the cellulose ether, and a mixture thereof.

  本发明提供了一种药物组合物，它对阿尔茨海默病、朊病毒病和淀粉样变性等构象疾病具有预防和/或治疗效果。本发明的药物组合物包括一种或多种纤维素醚作为活性成分，这些纤维素醚选自具有通式（1）所代表的结构单元的纤维素醚： 其中至少一个 R 选自 CH3、C2H5、CH2CH2OH、CH2CH(OH) 和 CH2COOM；而其他 R 为 H；M 选自 H、Na、K 和 Ca、 纤维素醚的碱金属盐、纤维素醚的脂肪族酸酯及其混合物。
• VEGF INHIBITORS FOR USE FOR PREVENTING AND/OR TREATING ACNE
  申请人：Galderma Research & Development

  公开号：EP3412288A1

  公开（公告）日：2018-12-12

  The present invention relates to the use of a VEGF inhibitor for use for preventing and/or treating acne.

  本发明涉及一种用于预防和/或治疗痤疮的血管内皮生长因子抑制剂。
• VEGF INHIBITORS FOR USE FOR PREVENTING AND/OR TREATING ATOPIC DERMATITIS
  申请人：Galderma Research & Development

  公开号：EP3650040A1

  公开（公告）日：2020-05-13

  The present invention relates to the use of a VEGF inhibitor for use for preventing and/or treating atopic dermatitis, and in particular AD associated with infection by Staphylococcus aureus.

  本发明涉及一种血管内皮生长因子抑制剂，用于预防和/或治疗特应性皮炎，尤其是与金黄色葡萄球菌感染相关的特应性皮炎。
• GLYCOSYLATED LYSOSOMAL PROTEINS, METHOD OF PRODUCTION AND USES
  申请人：eleva GmbH

  公开号：EP3271453B1

  公开（公告）日：2021-09-08